Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer's disease
- PMID: 38824476
- DOI: 10.1007/s00406-024-01827-7
Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer's disease
Abstract
This study aimed to investigate the cross-sectional associations between regional Alzheimer's disease (AD) biomarkers, including tau, β-amyloid (Aβ), and brain volume, within the Papez circuit, and neuropsychological functioning across the preclinical and clinical spectrum of AD. We utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including 251 Aβ-positive participants. Participants were categorized into three groups based on the Clinical Dementia Rating (CDR): 73 individuals with preclinical AD (CDR = 0), 114 with prodromal AD (CDR = 0.5), and 64 with clinical AD dementia (CDR ≥ 1). Linear regression analyses, adjusted for age, gender, and education years, were employed to evaluate the associations between five regions of interest (the hippocampus, para-hippocampus, entorhinal cortex, posterior cingulate cortex, and thalamus) and five neuropsychological tests across the three imaging modalities. In the preclinical stage of AD, flortaucipir PET was associated with impaired global cognition and episodic memory (range standardized β = 0.255-0.498, p < 0.05 corrected for multiple comparisons), while florbetapir PET and brain volume were marginally related to global cognition (range standardized β = 0.221-0.231, p < 0.05). In the clinical stages of AD (prodromal and dementia), both increased flortaucipir uptake and decreased brain volume were significantly associated with poorer global neuropsychological and episodic memory performance (range standardized β = 0.222-0.621, p < 0.05, most regions of interest survived correction for multiple comparisions). However, a slight relationship was observed between florbetapir uptake and poorer global cognitive function. The regions most affected by flortaucipir PET were the hippocampus, para-hippocampus, and posterior cingulate cortex. During the clinical stages, the hippocampus and entorhinal cortex exhibited the most significant volumetric changes. Tau PET and brain volume measurements within the Papez circuit are more sensitive indicators of early cognitive deficits in AD than Aβ PET. Furthermore, during the clinical stages of AD, both flortaucipir PET and brain volume of the Papez circuit are closely correlated with cognitive decline. These findings underscore the importance of integrating multiple biomarkers for the comprehensive evaluation of AD pathology and its impact on cognition.
Keywords: Alzheimer’s disease; Alzheimer’s disease neuroimaging initiative (ADNI); Brain volume; Flortaucipir PET; Papez circuit.
© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: None of the authors have any conflicts of interest associated with this study.
Similar articles
-
Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.Neurology. 2019 Feb 5;92(6):e601-e612. doi: 10.1212/WNL.0000000000006875. Epub 2019 Jan 9. Neurology. 2019. PMID: 30626656 Free PMC article.
-
Mapping amyloid beta predictors of entorhinal tau in preclinical Alzheimer's disease.Alzheimers Dement. 2025 Feb;21(2):e14499. doi: 10.1002/alz.14499. Epub 2025 Jan 8. Alzheimers Dement. 2025. PMID: 39777850 Free PMC article.
-
Impact of diabetes on the progression of Alzheimer's disease via trajectories of amyloid-tau-neurodegeneration (ATN) biomarkers.J Nutr Health Aging. 2025 Feb;29(2):100444. doi: 10.1016/j.jnha.2024.100444. Epub 2024 Dec 10. J Nutr Health Aging. 2025. PMID: 39662155 Free PMC article.
-
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.Alzheimers Dement. 2017 Apr;13(4):e1-e85. doi: 10.1016/j.jalz.2016.11.007. Epub 2017 Mar 22. Alzheimers Dement. 2017. PMID: 28342697 Free PMC article. Review.
-
Unraveling the Potential Underlying Mechanisms of Mild Behavioral Impairment: Focusing on Amyloid and Tau Pathology.Cells. 2024 Jul 8;13(13):1164. doi: 10.3390/cells13131164. Cells. 2024. PMID: 38995015 Free PMC article. Review.
Cited by
-
Evaluation of the Effects of Thymoquinone on RAGE/NOX4 Expressions and Brain Tissue Morphometry in Experimental Alzheimer's Disease Induced by Amyloid Beta 1-42 Peptide.Biomolecules. 2025 Apr 7;15(4):543. doi: 10.3390/biom15040543. Biomolecules. 2025. PMID: 40305274 Free PMC article.
References
-
- Weller J, Andrew B (2018) Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research 7:1161. https://doi.org/10.12688/f1000research.14506.1 - DOI
-
- Vogel JW, Etienne VP, Alexa PB, Angela T, Pierre O, Renaud LJ et al (2018) Brain properties predict proximity to symptom onset in sporadic Alzheimer’s disease. Brain 6:6. https://doi.org/10.1093/brain/awy093 - DOI
-
- Rik O, Ruben S, Tomas O et al (2019) Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology 92(6):e601–e612. https://doi.org/10.1212/WNL.0000000000006875 - DOI
-
- Reisa AS, Keith AJ et al (2013) Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individual. Neurobiol Aging 34(3):822–831. https://doi.org/10.1016/j.neurobiolaging.2012.06.014 - DOI
-
- Grazia D, Femminella T, Thayanandan V et al (2018) Imaging and molecular mechanisms of Alzheimer’s disease: a review. Int J Mol Sci 19(12):3702. https://doi.org/10.3390/ijms19123702 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical